PET-MR and SPECT-MR multimodality probes: Development and challenges

Chang-Tong Yang1,5,6,7, Krishna K. Ghosh1, Parasuraman Padmanabhan1, Oliver Langer3,4, Jiang Liu5, David Ng Chee Eng6,7, Christer Halldin1,2, Balázs Gulyás1,2

1. Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, 59 Nanyang Drive, Singapore 636921.
2. Karolinska Institutet, Department of Clinical Neuroscience, S-171 76, Stockholm, Sweden.
3. Department of Clinical Pharmacology and Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, A-1090, Vienna, Austria.
4. Center for Health and Bioresources, Biomedical Systems, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
5. Cixi Institute of Biomedical Engineering, Ningbo Institute of Industrial Technology and Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo, P.R. China, 315201.
6. Department of Nuclear Medicine and Molecular Imaging, Radiological Sciences Division, Singapore General Hospital, Outram Road, Singapore 169608.
7. Duke-NUS Medical School, 8 College Road, Singapore 169857.

Corresponding author: Chang-Tong Yang Email: yangct@ntu.edu.sg; yang.changtong@sgh.com.sg; chmyct@yahoo.com; Tel: (65)6326-5666.

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2018.04.11; Accepted: 2018.06.08; Published: 2018.11.29

Abstract

Positron emission tomography (PET)-magnetic resonance (MR) or single photon emission computed tomography (SPECT)-MR hybrid imaging is being used in daily clinical practice. Due to its advantages over stand-alone PET, SPECT or MR imaging, in many areas such as oncology, the demand for hybrid imaging techniques is increasing dramatically. The use of multimodal imaging probes or biomarkers in a single molecule or particle to characterize the imaging subjects such as disease tissues certainly provides us with more accurate diagnosis and promotes therapeutic accuracy. A limited number of multimodal imaging probes are being used in preclinical and potential clinical investigations. The further development of multimodal PET-MR and SPECT-MR imaging probes includes several key elements: novel synthetic strategies, high sensitivity for accurate quantification and high anatomic resolution, favourable pharmacokinetic profile and target-specific binding of a new probe. This review thoroughly summarizes all recently available and noteworthy PET-MR and SPECT-MR multimodal imaging probes including small molecule bimodal probes, nano-sized bimodal probes, small molecular trimodal probes and nano-sized trimodal probes. To the best of our knowledge, this is the first comprehensive overview of all PET-MR and SPECT-MR multimodal probes. Since the development of multimodal PET-MR and SPECT-MR imaging probes is an emerging research field, a selection of 139 papers were recognized following the literature review. The challenges for designing multimodal probes have also been addressed in order to offer some future research directions for this novel interdisciplinary research field.

Key words: bimodality imaging probe, PET-MR, SPECT-MR, contrast agent, radioligand

Introduction

Molecular imaging can provide us with a deeper understanding of biological processes at molecular and cellular levels [1]. Molecular imaging has received considerable interest during the last few decades because of its momentous potential in diagnosis and treatment monitoring for both preclinical and clinical applications. Several molecular imaging techniques, including optical fluorescence imaging, MRI, PET and SPECT, are extensively used nowadays [2, 3]. These non-invasive imaging modalities have various characteristics based on their underlying physical and technical principles. One single imaging modality may not be sufficient to obtain all necessary information and each single
molecular imaging technique has its own strengths and drawbacks: each may vary in spatial and temporal resolution, depth of subject penetration, detection threshold, etc. [4]. For example, optical fluorescence imaging offers high sensitivity, specificity and resolution, but it suffers from limited tissue penetration leading to limited application for quantification of the target in deep tissues within a subject [5]. Some modalities such as PET and SPECT, which have been used extensively to visualize metabolic and physiological process, offer very high sensitivity (in the pico-nano-molar range) but provide relatively poor anatomic resolution [6-8]. On the other hand, primarily anatomical imaging modalities such as MRI and CT have been used to detect anatomical structures because of their high spatial resolution, but with relatively poor sensitivity (in the millimolar range). MRI also enables high soft tissue contrast studies using it in magnetic resonance spectroscopic (MRS) and functional magnetic resonance imaging (fMRI) application modes [9-11].

A combination of two or more imaging modalities such as PET-CT or SPECT-CT can yield complementary information regarding morphology and function in preclinical and clinical applications, and thereby such type of hybrid and/or multimodalities can provide us with synergistic advantages over single modalities alone. Utilizing PET-CT hybrid imaging is an effective approach for combining physiological and morphological information in preclinical and clinical investigations [12]. However, the combined PET and CT scan may cause errors during the co-registration of images [13, 14]. Moreover, CT scans are associated with high radiation doses. By combining PET with the MR technique, the limited spatial resolution of PET or SPECT can be overcome by providing anatomical MR images, in which regions of interest can be accurately defined. Compared to CT, the MR spectroscopic technique can provide a series of biochemical and spatially localized metabolic information, and it does not require any radiation that could cause a problem in case of follow-up studies for young patients [15, 16]. The complementary information obtained from PET/SPECT and MR scans can potentially improve the detection of biomarkers and disease diagnosis. The ability to correlate the physiological information obtained from PET or SPECT images with the anatomical information obtained from MR images is an efficient method to identify and localize abnormal tissue accurately [17-19]. There are mainly two different designs for combining PET-MR: sequential and simultaneous acquisition approaches. It is exceptionally important to design a PET-MR combined system without compromising the performance of standalone PET and MR systems. However, the technical challenges triggered by the presence of magnetic field make the combination of PET-MR modalities very challenging. The deleterious interactions caused by the high magnetic field of the MR scanner and the radiofrequency (RF) interference between the MR and PET need to be tackled.

This review gives a comprehensive overview of all noteworthy PET-MR and SPECT-MR multimodal imaging probes including small molecule Gd³⁺-chelate-containing bimodal probes, nano-sized bimodal, small molecular and nano-sized trimodal probes. Rather than concentrating on certain classes of bimodal imaging probes [20-23] or on one aspect of bimodal probes such as potential clinical applications [24] or nano-sized dual probes [25], the present review is going to summarize systematically all presently available PET-MR and SPECT-MR multimodal imaging probes, obtained with various synthetic methodologies, having various physicochemical properties, and showing potentials for preclinical and clinical applications. Finally, the challenges for designing multimodal probes have been addressed in order to offer some future research directions for this interdisciplinary research field.

**Small molecular bimodal probes**

Gd³⁺ chelates are the most commonly used small molecule MRI contrast agents (CAs) due to seven unpaired electrons of Gd³⁺ in the f orbital. These Gd-based CAs are extensively studied for contrast enhancement relying on T₁ relaxivity. Gd³⁺ chelates have been incorporated into other imaging modality reporters such as PET or SPECT moieties to develop bimodal probes. Small molecular Gd³⁺ chelate-containing bimodal imaging probes with their applications are summarized in **Table 1**. A small molecule gadolinium compound Gd-DOTA-4AMP-F was reported as a T₁-weighted PET-MR imaging bimodal probe [26]. The imaging probe (**Figure 1**) is composed of two reporters: a Gd-DOTA-based MR imaging reporter, which was designed to be pH-responsive, and the PET radionuclide ¹⁸F, which was attached to the organic moiety of the molecule. This pH-responsive CA is a potential biomarker of tumors [27] with a ¹⁸F PET reporter to provide quantification and measurements of the concentration of the probe in the tissue of interest.

**Table 1.** Small molecular bimodal probes and their applications.

| Probe | PET(SPECT) reporter | MR reporter | Applications | Ref. |
|-------|---------------------|-------------|--------------|------|
| Gd-DOTA-4AMP-¹⁸F | ¹⁸F | Gd-DOTA | Quantitative pH mapping | 26 |
| ⁶⁸GaTRAP(HMDA)-[DOTA]₄G ⁶⁸Ga | ⁶⁸Ga | Gd-DOTA | Functional PET-MR imaging | 30 |
| [Gd(Ⅳ)[¹⁶⁶Ho-L] | ¹⁶⁶Ho | Gd-DOTA | pH-mapping | 31 |

http://www.thno.org
Conjugates of Gd$^{3+}$-containing CA and additional chelators for potential PET/SPECT radiometallic ions such as Cu$^{2+}$, Ga$^{3+}$, In$^{3+}$ were reported [28, 29]. The challenge lies in replacement of these radiometallic ions at a specific coordination site. Radiolabeling of responsive Gd$^{3+}$-containing MRI CA with $^{68}$Ga as small-molecular PET-MR probes $^{68}$GaTRAP(HMDA-[DOTA]-Gd)$_3$ for simultaneous PET and MR acquisition was developed [30] (Figure 2). Due to its smaller macrocyclic ring compared with DOTA, the TRAP has extraordinary Ga$^{3+}$ affinity to promote thermodynamic formation of the $^{68}$Ga(TRAP)] complexes. MR signal enhancement in the functional imaging requires simultaneous mapping of CA concentration and quantitative assessment from PET data. The synthetic strategy provided a model to explore application of smart MR imaging probes for medical diagnosis through simultaneous PET-MR imaging. A dual SPECT-MRI pH-responsive probe [Gd-L]$[^{166}$Ho-L] was developed by exchanging some of the Gd$^{3+}$ with the SPECT radioisotope $^{166}$Ho. The MRI reporter and the SPECT reporter differ only in the coordinated lanthanide ion in which the SPECT reporter was used to calculate the concentration of CA for measuring the pH [31] (Figure 3).

Nano-sized bimodal probes
Most of PET-MR and SPECT-MR bimodal imaging probes are nanoparticles or nano-sized structures because it is difficult for small molecules to carry two or more imaging reporters and even targeting groups as a single entity due to their limited loading capacity. Nano-structures have chemical and structural characteristics such as high surface area, controlled shape and size, and tuneable chemical reactivity at the surface, on coatings and inside the particle, etc. The advantages of nano-sized structures allow for carrying multimodal imaging reporters and targeting biomolecules. Approaches for development of novel multimodal PET-MR probes are mainly through surface modifications by conjugating a MR imaging reporter such as paramagnetic Gd$^{3+}$ or superparamagnetic iron oxides (SPIOs), and by incorporating a PET radionuclide together with other functionalities. All nano-sized PET-MR and SPECT-MR bimodal imaging probes with their applications are summarized in Table 2.

A PET-MR probe $^{64}$Cu-DOTA-ADIO is composed of dextran sulfate-coated SPIO nanoparticles conjugated to $^{64}$Cu-labeled chelates [32]. This is one of the earliest scientific literature about bimodal PET-MR imaging probes. Bifunctional chelator $p$-SCN-Bz-DOTA (S-(2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane -1,4,7,10-tetraacetic acid) was coordinated with $^{64}$Cu first, which formed a thermodynamically stable chelate, then the radiolabeled chelate was conjugated to the nanoparticles. The coordination of $^{64}$Cu to chelator before the conjugation to nanoparticles resulted in a low yield of bimodal probe. By changing the chelator from p-SCN-Bz-DOTA to amine-Bz-DOTA, the radiolabeling yield increased dramatically as the linker ethylenediamine decreased the steric hindrance between the chelator and SPIO nanoparticles. A different strategy was employed for preparing radiolabeled micelle-coated SPIOs by using DOTA-conjugated phospholipids [33]. SPIOs coated with PEGylated phospholipids by hydrophobic
interaction between the capping agents on the nanoparticle surface and acyl chain of phospholipids were conjugated with DOTA-NHS-ester, then radiolabeled with $^{64}$Cu in the last step to achieve high yield and high purity with a hydrodynamic diameter of $20.3 \pm 1.9$ nm (Figure 4, left). Phantom studies showed that SPIO cores in $^{64}$Cu-mSPIO have a dark image at high iron concentration, while a strong PET signal was observed from $^{64}$Cu-labeled PEG-phospholipid micelle-coated SPIO nanoparticles (Figure 4, right). As a bimodal PET-MR imaging probe, the administered dose of $^{64}$Cu-labeled nanoparticles needs to be within the detection limits of two modalities for in vivo imaging studies. The biodistribution and microPET-CT imaging studies demonstrated a long blood circulation of the probe in BALB/c mice, contributed by the lipid-PEG coating.

Although PET tracers are able to locate the intratumoral areas of uptake with higher spatial resolution, the advantages of combining PET with MRI can provide the possibility of making use of MR images to correct for PET partial-volume effects and to favor PET image reconstruction [34]. Radiolabeled SPIOs conjugated with tumor-specific targeting moieties have been explored as bimodal PET-MR or SPECT-MR probes for tumor imaging and cancer therapy [35-39]. Polyalaspartic acid (PASP)-coated SPIO nanoparticles functionalized with cyclic arginine-glycine-aspartic (RGD) peptides for integrin $\alpha_\mathrm{v}\beta_3$ targeting and DOTA for $^{64}$Cu labeling were developed as dual PET-MR probes of tumor integrin $\alpha_\mathrm{v}\beta_3$ expression (Figure 5) [40]. The SPIO nanoparticles core serving as MR imaging detecting unit were coated with PASP through the carboxyl group; the remaining amine group was used for conjugation with DOTA to radiolabel $^{64}$Cu as PET detecting unit, and to linker NHS-poly(ethylene glycol) (PEG)-maleimide (MAL) for RGD peptides as tumor-targeting unit for integrin $\alpha_\mathrm{v}\beta_3$ positive tumors. In vivo PET studies showed that specific binding to tumor reached the highest value ($10.1 \pm 2.1$ %ID/g) at 4 h after injection of $^{64}$Cu-DOTA-IO-RGD (Figure 6, left). Blocking studies confirmed the specificity toward $\alpha_\mathrm{v}\beta_3$ receptor. In vivo MR imaging studies using T2-weighted fast spin-echo on U87MG tumor-bearing mice demonstrated that the signal intensity decreased more after an injection of DOTA-IO-RGD compared with an injection of DOTA-IO and a co-injection of integrin $\alpha_\mathrm{v}\beta_3$-blocking agent (Figure 6, right).

Table 2. Nano-sized bimodal probes and their applications.

| Probe | PET(SPECT) reporter | MR reporter | Applications | Ref. |
|-------|---------------------|-------------|--------------|------|
| $^{64}$Cu-DOTA-ADIO | $^{64}$Cu | SPIO | Atherosclerotic plaques | 32 |
| $^{64}$Cu-DOTA-mSPIO | $^{64}$Cu | SPIO | Disease detection and treatment in atherosclerosis and cancer models | 33 |
| $^{64}$Cu-NOTA-SPIO-cRGD-DOX | $^{64}$Cu | SPIO | U87MG human glioblastoma cell targeting | 35 |
| $^{64}$Cu-DOTA-SPION | $^{64}$Cu | USPIO | Earlier neoplastic lesion detection | 36 |
| $^{125}$I-RGD-SPIO | $^{125}$I | USPIO | Integrin $\alpha_\mathrm{v}\beta_3$ expression in breast cancer | 37 |
| $^{111}$In-DOTA-diScFv-NP | $^{111}$In | SPIO | MUC-1 expression in glandular epithelial cells and AMF therapy | 38 |
| $^{111}$In-DOTA-ChI6 | $^{111}$In | SPIO | Breast cancer and alternating magnetic field (AMF) therapy | 39 |
| $^{64}$Cu-DOTA-IO-RGD | $^{64}$Cu | SPIO | U87MG human glioblastoma cell line, tumor $\alpha_\mathrm{v}\beta_3$ integrin expression | 40 |
| $^{111}$In-Sa-MnEOH | $^{111}$In | MnFe$_2$O$_4$ | Axillary and brachial lymph nodes (LNs) imaging | 41 |
| $^{64}$Cu-NOTA-IO-Man | $^{64}$Cu | SPIO | LNs imaging | 42 |
| $^{111}$In-nAAMB-SPION | $^{111}$In | SPION | Mesothelioma imaging | 43 |
| $^{64}$Cu-dhcp-SPION | $^{64}$Cu | SPIO | LNs mapping | 44 |
| $^{64}$Cu-dtcp-MnFe$_2$O$_4$ and $^{18}$F-MnFe$_2$O$_4$ | $^{64}$Cu and $^{18}$F | MnFe$_2$O$_4$ | Targeted organs (liver, spleen) | 45 |
| $^{89}$Tc-SPIONs | $^{89}$Tc | SPION | SLN mapping | 46 |
| $^{64}$Cu-NOTA-MagH-1-PNPs | $^{64}$Cu | SPIO | PET-MR diagnostic probe | 47 |
| $^{89}$Tc-USPIO | $^{89}$Tc | USPIO | MPS theranostic probe | 48, 49 |
| $^{64}$Cu-DTPA-USPIO | $^{64}$Cu | SPIO | MPS theranostic probe | 50 |
| $^{89}$Tc-DPA-ale Endorem | $^{89}$Tc | SPION | MPS system imaging | 51 |
| $^{89}$Tc-DOTA-SPION-BS-USPIO | $^{89}$Tc | USPIO | Cardiovascular imaging | 52 |
| $^{89}$Tc-DOTA-SPION-LBA | $^{89}$Tc | SPION | Hepatocyte imaging | 54 |
| $^{64}$Cu-DOTA-MDIO | $^{64}$Cu | SPIO | Macrophage-targeting atherosclerotic plaque imaging | 55 |
| $^{64}$Cu-DOTA-IO | $^{64}$Cu | SPIO | Vascular inflammation mapping | 56 |
| $^{64}$Cu-NOTA-IO-IoNP | $^{64}$Cu | SPIO | HT-29 colon cancer cells targeting | 57 |
| $^{64}$Cu-DOTA-IO-GUL | $^{64}$Cu | SPIO | Prostate-specific membrane antigen (PSMA) | 58 |
| $^{89}$Tc-USPIO-C595 | $^{89}$Tc | USPIO | Breast cancer and MPS | 59 |
| $^{11}$C-SPION | $^{11}$C | SPION | Liver imaging | 60 |
| $^{60}$Fe-Os-Ag$_{239}$I heterodimer | $^{60}$Fe | SPIO | MPS uptake | 61 |
| $^{99m}$Tc-DFO-ferumoxtran-10 | $^{99m}$Tc | SPIO | Prostate cancer and LNs diagnosis | 62 |
| $^{64}$Cu-SPIO | $^{64}$Cu | SPIO | Chelator-free radiolabeling | 63 |
| $^{89}$Zr | $^{89}$Zr | Rhodamine | Chelator-free radiolabeling | 64 |
| $^{90}$Y | $^{90}$Y | Rhodamine | Chelator-free radiolabeling | 65 |
| $^{111}$In | $^{111}$In | SPIO | Chelator-free radiolabeling | 66 |
| $^{201}$Tl | $^{201}$Tl | SPIO | Chelator-free radiolabeling | 67 |
| $^{111}$In | $^{111}$In | SPIO | Chelator-free radiolabeling | 68 |
| $^{89}$Zr | $^{89}$Zr | SPIO | Chelator-free radiolabeling | 69 |
| $^{64}$Cu | $^{64}$Cu | SPIO | Chelator-free radiolabeling | 70 |
| $^{111}$In | $^{111}$In | SPIO | Chelator-free radiolabeling | 71 |
| $^{89}$Zr | $^{89}$Zr | SPIO | Chelator-free radiolabeling | 72 |
| $^{64}$Cu | $^{64}$Cu | SPIO | Chelator-free radiolabeling | 73 |
| $^{89}$Zr | $^{89}$Zr | SPIO | Chelator-free radiolabeling | 74 |

http://www.thno.org
$^{99m}$Tc-BP-S-MWNT  $^{99m}$Tc SPION In carbon nanotubes for MPS uptake 83, 84
$^{68}$Ga-AuIX-DOTA-Gd  $^{68}$Ga Gd-DOTA Intra venous injection for biodistribution 85
Gd(DOTA)$^{111}$In(DOTA)SRPs  $^{111}$In Gd-DOTA Intra venous injection for biodistribution 87
GdAcAc-DTPA-$^{166}$Ho and $^{99m}$Tc GdAcAc In liposome for diagnosis and therapy 90
GaAcAc-DTPA-$^{68}$Ga  $^{68}$Ga Gd-DOTA Intra venous injection for biodistribution 85
$^{89}$Zr-Gd-DTPA-OL  $^{89}$Zr Gd-DTPA In liposome for imaging of cancer 91
$^{64}$Cu-EF-2104R  $^{64}$Cu Gd-DOTA Fibrin-targeted thrombus imaging 93, 94
$^{99m}$Tc-Bis-pyridyl-lysine-caproyl-phosphatidylthanolamine-Gd-DTPA  $^{99m}$Tc Gd-DTPA αvβ3 integrin targeted Vx2 rabbit tumor 95

Figure 4. (Left) Schematic representation of dual-modality $^{64}$Cu-mSPIO. (Right) PET and MR imaging of $^{64}$Cu-mSPIO phantoms. (A) T2-weighted image of 25 µg Fe/mL (bottom) of $^{64}$Cu-labeled magnetic nanoparticles (scale bar corresponds to high and low iron concentration). (B) Decay-corrected microPET image of 25 µg Fe/mL (top) and 10 µg Fe/mL (bottom) of $^{64}$Cu-labeled magnetic nanoparticles (scale bar corresponds to high and low copper-$^{64}$ concentration). Adapted with permission from [33], copyright 2010 American Chemical Society.

Figure 5. Illustration of PET-MRI probe based on IO nanoparticles. Adapted with permission from [40], copyright 2008 Society of Nuclear Medicine and Molecular Imaging.

Figure 6. (Left) Decay-corrected whole-body coronal PET images of nude mice bearing human U87MG tumor at 1, 4, and 21 h after injection of 3.7 MBq of $^{64}$Cu-DOTA-IO, $^{64}$Cu-DOTA-IO-RGD, or $^{64}$Cu-DOTA-IO-RGD with 10 mg of c(RGDyK) peptide per kg (300 µg of iron-equivalent IO particles per mouse). (Right) T2-weighted MR images of nude mice bearing U87MG tumor before injection of IO nanoparticles (A and E) and at 4 h after tail-vein injection of DOTA-IO (B and F), DOTA-IO-RGD (C and G), and DOTA-IO-RGD with blocking dose of c(RGDyK) (D and H). Adapted with permission from [40], copyright 2008 Society of Nuclear Medicine and Molecular Imaging.

http://www.thno.org
Radiolabeled SPIOs as bimodal probes have potential clinical applications in the preoperative localization and characterization of sentinel lymph nodes (SLNs), which could provide information of their pathology for investigation of tumor metastasis. SPIOs with a composition of MnFe₂O₄ (MnMEIO) coated with serum albumin (SA) were used to radiolabel the protein with ¹²⁴I (¹²⁴I-SA-MnMEIO) as a bimodal imaging probe to image SLNs in vivo [41]. ¹²⁴I-SA-MnMEIO can be directly radiolabeled by conjugation of radionuclide ¹²⁴I to the ortho position of tyrosine residue in SA through using Iodo-Beads. ¹²⁴I ion from Iodo-Beads in solution will be oxidized to form a reactive ¹²⁴ICl, which reacts with the ortho position of tyrosine. Two different LNs, brachial and axillary LNs, could be clearly identified and localized in PET-MR fusion image; though, axillary LN was unambiguously spotted when MRI single modality was used only due to its location far from the injection site compared with brachial LN (Figure 7). Since SLNs are located deep inside tissue, it is quite challenge to image SLNs. This example demonstrated the advantages of using a PET-MR bimodal probe to image SLNs, which can be used to further evaluate the metastatic status of a tumor.

Figure 7. (a–f) PET-MR images of SLNs in a rat at 1 h post injection of ¹²⁴I-SA-MnMEIO into the right forepaw (I = nanoprobe injection site). Coronal (a) MR and (b) PET images in which a brachial LN (white circle) is detected. c) The position of the brachial LN is well matched in a PET-MR fusion image. Four small pipette tips containing Na¹²⁴I solution were used as a fiducial marker (white arrowheads) for the concordant alignment in PET-MR images. In the transverse images, axillary (red circle) and brachial LNs (white circle) are detected in the d) MR and e) PET images, and images of each node are nicely overlapped in the corresponding PET/MR fusion image (f). g) The explanted brachial LN also shows consistent results with in vivo images by PET and MR. Only the LN from the right-hand side of the rat containing ¹²⁴I-SA-MnMEIO shows strong PET and dark MR images. The schematics of the rat in the h) coronal and i) transverse directions show the locations of the LNs. Adapted with permission from [41], copyright 2008 Wiley-VCH.

A dual PET-MR imaging probe ⁶⁸Ga-NOTA-IO-MAN was synthesized by a new methodology for targeting LNs [42]. SPIOs were encapsulated in a solution of polysorbate 60 with functionalized amphiphiles—NOTA conjugated with stearylamine (NOTA-SA) and α-D-mannopyranosylphenyl isothiocyanate conjugated with stearylamine (Man-SA); the resulting monodisperse and stable SPIOs were radiolabeled with ⁶⁸Ga for PET-MR imaging of LNs. When ¹¹¹In-labeled anti-mesothelin antibody (mAbMB) was conjugated to the SPIO nanoparticles, a dual-modal imaging probe was developed for SPECT-MR imaging of mesothelin-expressing cancers [43]. The bimodal imaging provided functional and anatomical information for early diagnosis and treatment planning of these cancers.

A different strategy was developed to radiolabel clinically approved SPIOs such as Endorem/Feridex. A bifunctional chelator dithiocarbamate bisphosphonates (DTCBP) was conjugated with Endorem with high affinity for both the metallic radionuclide ⁶⁴Cu and dextran-coated SPIO nanoparticles to facilitate the radiolabeling in high yields, providing a highly stable bimodal probe both in vitro and in vivo (Figure 8, left) [44]. However, the disadvantage of this probe is that radiolabeling of ⁶⁴Cu to the DTCBP needs to be done before conjugation with Endorem, resulting in low specific activity of the tracer. Preclinical PET-MR imaging studies of C57BL/6 mice demonstrated that the MR signal decreased significantly in the popliteal LNs (Figure 8, right (B)), PET-CT images showed uptake of [⁶⁴Cu(DTCBP)₂]-Endorem in the popliteal LNs and less uptake in the iliac LNs (Figure 8, right (C) and (D)). No translocation of [⁶⁴Cu(DTCBP)₂]-Endorem was found. PET-MR imaging studies confirmed the dual probe’s potential for imaging SLN in a non-tumor model. A similar strategy used an aluminium hydroxide coating to stabilize the magnetic nanoparticles Fe₃O₄ and MnFe₂O₄ as dual modality PET-MR probes [45]. SPIOs radiolabeled with ⁹⁹mTc were reported as a dual SPECT-MR probe feasible for imaging SLNs [46]. Both SPECT and MR images showed the accumulation of ⁹⁹mTc-SPIOs in LNs after subcutaneous injection in rats. The high uptake of ⁹⁹mTc-SPIOs found in SLN from biodistribution studies indicated ⁹⁹mTc-SPIOs could have future applications in breast cancer and malignant melanoma.
Figure 8. (Top) Radiolabeling of dextran-coated iron oxide nanoparticles such as Endorem using radiolabeled bisphosphonates (BPs). (Bottom) In vivo PET-MR imaging studies with \[ ^{64}\text{Cu(dtcbp)}_{2}\]Endorem in a mouse. (A, B) Coronal (top) and short axis (bottom) MR images of the lower abdominal area and upper hind legs showing the popliteal lymph nodes (solid arrows) before (A) and after (B) footpad injection of \[ ^{64}\text{Cu(dtcbp)}_{2}\]Endorem. (C) Coronal (top) and short-axis (bottom) NanoPET-CT images of the same mouse as in (B) showing the uptake of \[ ^{64}\text{Cu(dtcbp)}_{2}\]Endorem in the popliteal (solid arrow) and iliac lymph nodes (hollow arrow). (D) Whole-body NanoPET-CT images showing sole uptake of \[ ^{64}\text{Cu(dtcbp)}_{2}\]Endorem in the popliteal and iliac lymph nodes. No translocation of radioactivity to other tissues was detected. Adapted with permission from [44], copyright 2011 Wiley-VCH.

The nanoparticle size and coating of radiolabeled SPIOs are crucial for the dual modal probe’s biodistribution, which can affect the excretion pattern of the probe. Maghemite nanoparticles were encapsulated in poly(D,L-lactide-co-glycolide)-block-poly(ethylene glycol) copolymer (PLGA-b-PEG-COOH), resulting in better biocompatibility for hybrid imaging [47]. The biodistribution of \(^{99m}\text{Tc}\)- or \(^{67}\text{Ga}\)-radiolabeled ultra SPIO nanoparticles in Balb/c mice showed high uptake in reticuloendothelial organs such as spleen and liver [48-50]. The \(^{99m}\text{Tc}\)-radiolabeled bisphosphonate (BP), \(^{99m}\text{Tc}\)-dipicolylamine-alendronate (\(^{99m}\text{Tc}\)-DPA-ale), can be directly conjugated to the surface of uncoated SPIO nanoparticles, as was firstly reported for a SPECT-MR dual-modal probe [51]. \(^{99m}\text{Tc}\)-DPA-ale binds to the core of Endorem, where it does not affect the dextran coating of the nanoparticles. This provided a synthetic methodology for the BP group to attach functional groups to the SPIO nanoparticles. However, a short circulation time was found in the biodistribution studies because the radiolabeled nanoparticles were quickly taken up by macrophages of the mononuclear phagocyte system (MPS). A new type of ultra-small SPIO with a coating based on a bisphosphonate-anchored PEGylation (PEG(5)-BP-USPIO) was developed to prevent uptake by MPS and resulted in extended circulation times (Figure 9) [52,53]. The stable hydrophilic PEGylation coating led to colloidal stability of PEG(5)-BP-USPIO. PEG(5)-BP-USPIOs demonstrated high r1 and low r2 relaxivities, making it an effective T1-weighted contrast agent. Considerable signal increase from in vivo MRI studies indicated its high potential for MR angiography. In vivo SPECT studies confirmed its long blood circulation time and revealed its decomposition and excretion patterns. Through synthetic design and chemical modifications, the radiolabeled SPIO nanoparticles can be developed as targeted hybrid imaging probes, such as for hepatocytes targeting by surface modification with lactobionic acid [54], macrophages targeting via scavenger receptor type A by modification with maleic anhydride to increase the negative charge [55, 56], and HT-29 cancer cells [57], prostate-specific membrane antigen [58] and MUC-1-positive breast cancer cells targeting [59] by conjugation with oleanolic acid, glutamate-urea-lysine and monoclonal antibody C595 mAb, respectively. However, their in vivo targeting ability would be affected due to coverage of the targeting sites by protein corona [59].

Figure 9. Long-circulating bimodal nanoparticles for PET-MR and SPECT-MRI. (A) Bisphosphonate anchors allow strong and stable binding of PEG polymers and radionuclides on the surface of the USPIOs. (B) The bimodal nanoparticles circulate in the bloodstream, as indicated by the strong imaging signal in the heart and vessels. Adapted with permission from [52], copyright 2013 American Chemical Society.

New synthetic strategies for preparing SPIO nanoparticle-based bimodal PET-MR and SPECT-MR probes are emerging. Carbon-11 radiolabeled SPIOs are one example [60]. Similar to routine radiolabelling
of small molecular carbon-11-containing PET tracers, carbon-11 from the $[^{11}C]$methyl iodide reacts with carboxylic acid (-COOH) and amine (-NH$_2$) functional groups at the surface of SPIO nanoparticles via N- and O-methylation. Due to nanoparticle agglomeration, the proof-of-concept methodology needs to be improved to increase radiochemical yield before the bimodal probe can be applied to in vivo studies. Novel dual-modality probes, $^{125}$I-radiolabel Fe$_3$O$_4$-Ag$^{125}$I heterodimer nanoparticles, were synthesized through direct reaction of sodium iodine-$^{125}$I with Fe$_3$O$_4$-Ag hetero-structured nanoparticles [61]. Radiolabeling of $^{89}$Zr to the organic coating of SPIOs was reported as a bimodal probe to image SLN [62]. The carbohydrate-coated SPIO nanoparticle Ferumoxytol, an FDA-approved drug for MRI contrast and the treatment of iron deficiency anemia, was conjugated to desferrioxamine (DFO) chelate to generate the PET-MR dual modal probe $^{89}$Zr-DFO-labeled ferumoxytol ($^{89}$Zr-ferumoxytol) for mapping deep-tissue LNs (Figure 10). As a synthetic strategy, $^{89}$Zr-DFO has been employed to conjugate the albumin colloid covalently for preclinical drainage mapping of LNs in rabbit [63] and man [64], respectively. The conjugation did not significantly affect the physicochemical properties and consequent relaxivities of the nanoparticles. PET-MR studies showed that $^{89}$Zr-ferumoxytol can not only localize the drainage to the brachial and axillary LN in healthy mice but also can map the draining lymphatics in the disease mouse model [62].

Chelator-free approaches and core-doping for radiolabeling nanoparticles have been used for development of PET/SPECT-MR bimodal probes. Radiometals can be attached to the nanoparticle surface or incorporated into the particle core. The synthesis of dextran-coated $^{64}$Cu-doped iron oxide nanoparticles was reported as the first example of core-doped $^{64}$Cu particles. The $^{64}$Cu radionuclide was added to the reaction mixture before nanoparticle synthesis so that the radionuclide could be incorporated straightforwardly into the nanoparticle core during subsequent standard synthesis of the dextran-coated USPIOs [65]. Microwave heating-induced chelator-free $^{64}$Cu doping of USPIOs was elegantly demonstrated. A similar heat-induced method was employed to synthesize chelator-free radiolabeled $^{89}$Zr-Feraheme (FH) nanoparticles (Figure 11) [66]. This experimental approach can be applicable to other radiometals such as $^{64}$Cu and $^{111}$In with different oxidation states. The in vitro ligand exchange and plasma stability studies showed $^{89}$Zr-FH was thermodynamically and kinetically stable. PET-CT imaging and biodistribution studies showed that the physical and biological properties of the FH nanoparticles were not affected by $^{89}$Zr radiolabeling. More recently, heat-induced radiolabeling nanoparticles with radiometal were reported as multimodal and multifunctional probes, by a mature synthetic protocol [67], by using click chemistry to attach alkyne azide as a linker to conjugate with bioactive group [68], for promising applications such as monocyte tracking [69] and characterization of mature B cell accelerating wound healing [70]. A microwave-driven protocol was used for fast synthesis of $^{68}$Ga-radiolabeled SPIONs as the first example of $^{68}$Ga core-doped nanoparticles for PET-MR imaging [71]. Chelator-free radiolabeling, was developed as a highly efficient strategy for synthesis of arsenic$^{3+}$ and arsenic$^{5+}$ ions-radiolabeled SPIONs as PET-MR probes. Both As$^{3+}$ and As$^{5+}$ radiometal ions display high affinity and specific chemical reactivity with the surface of SPIONs through radiolabeling reaction [72]. Chelator-free radiolabeling was applied to incorporate radiometal ions such as $^{57}$Co, $^{67}$Ga, $^{64}$Cu into SPIONs to provide PET/SPECT-MR probes. The radiochemical yields depended on reaction conditions such as temperature, pH and reaction time, which were investigated and optimized. The $^{57}$Co, $^{67}$Ga, $^{64}$Cu-radiolabeled SPIONs were sterically stable. No dissociated radionuclides from the nanoparticles in various physiological media were detected [73].
Inspired by the technology that the parent $^{68}$Ge radionuclide in the $^{68}$Ge/$^{68}$Ga generator is bound to metal oxide TiO$_2$, the SPIONs were labeled with $^{89}$Ge in the absence of a chelator as a PET-MR probe. By incorporating PET radionuclides such as $^{68}$Ge and $^{59}$Fe into SPIOs without a chelator during the nanoparticle synthesis is one of the new synthetic approaches to generating multimodal nanoparticles. For example, a dual PET-MR probe $^{68}$Ge-SPION@PEG was prepared by incorporating $^{68}$Ge, which was generated by $^{68}$Ga(p,n)$^{68}$Ge from a cyclotron, into SPIOs for imaging SLN. The hydrophilic coating poly(acrylic acid) (PAA) of SPION was PEGylated to increase the in vivo stability (Figure 12, left). Uptake of $^{68}$Ge-SPION@PEG in normal BALB/c mice in the popliteal LN from in vivo PET images and contrast enhancement in MR images demonstrated its application in LN mapping $^{[74]}$ (Figure 12, right). Different preparation methods to incorporate $^{59}$Fe into SPIOs were reported $^{[75]}$. An efficient post-synthesis radiolabeling of monodisperse SPIOs, which were derived from high thermal decomposition of precursor and stabilized by oleic acid, was achieved through incubation with $^{59}$Fe. Core labeling of $^{59}$Fe can overcome the issue of probe stability in vivo, in which the radiolabelling moiety would decompose from the nanostructure. $^{14}$C-oleic acid was used to stabilize the SPIOs during the synthesis. Only a small amount of oleic acid was replaced by the polymer during encapsulation. In vivo studies of $^{59}$Fe-SPIOs provided a precise biological profile. However, direct incorporation of radionuclide into SPIOs was potentially only used in preclinical studies such as biodistribution, specific targeting, and metabolism of functional nanoparticles.

Carbon nanotubes (CNTs) have been used as promising nanomaterials in biomedicine $^{[76]}$; they have been proposed as a useful nanoplatform for PET/SPECT-MR imaging probes. One of the synthetic strategies for preparing CNTs-based imaging probes is to form hybrid nanostructures either by filling the cavity with imaging reporters or by external attachment of imaging reporters. For example, PET/SPECT radionuclides-labeled chelates were conjugated to the external CNT walls for both diagnosis and therapeutics $^{[77-79]}$. Gd$^{3+}$ was loaded to CNTs $^{[80]}$ and SPION was attached to CNTs $^{[81]}$ as positive and negative CAs, respectively. Conjugation of SPION to multi-walled CNTs (MWNTs) through electrostatic interactions could be used for diagnosis of liver metastases $^{[82]}$. CNTs were further used as a nanoplatform for carrying dual SPECT-MR probes. The SPIO nanoparticles were attached to one end of the nanotubes. The resulting SPION-decorated MWNTs were radiolabeled with $^{99m}$Tc through a functionalized bisphosphonate (dipicolylamine-alendronate, DPAale) on the carbon nanotube surface as opposed to non-selective adsorption of the radioisotope to the MWNTs $^{[83]}$ (Figure 13). In vivo biodistribution and MR imaging studies showed remarkable MR signal enhancement for the shortened hybrid CNTs compared to their longer hybrid counterparts $^{[84]}$. 

---

**Figure 11.** Reaction of FH with $^{89}$Zr$^{4+}$ ion salts (oxalate or chloride) to give radiolabeled $^{89}$Zr-FH. Adapted with permission from $^{[66]}$, copyright 2015 Royal Society of Chemistry.

**Figure 12.** (Left) A schematic illustration of chelator-free synthesis of $^{68}$Ge-metal oxides. (Right) a) In vivo lymph node imaging with PET after subcutaneous injection of $^{68}$Ge-SPION@PEG into the left footpad of the mouse. Lymph nodes and paws are indicated by green and red arrows, respectively. b) Quantification of the $^{68}$Ge-SPION@PEG uptake in the lymph node and mouse paw ($n = 3$). c) In vivo lymph node mapping with MRI before and after injection of Ge-SPION@PEG into the left foot pad of the mouse. Obvious darkening of the lymph node can be seen (dashed green circle), whereas no contrast enhancement is observed for the contralateral lymph node (dashed red circle). Adapted with permission from $^{[74]}$, copyright 2014 Wiley-VCH.
Small and rigid platforms (SRPs) of polysiloxane matrix-based Gd$_2$O$_3$ core-SiO$_x$ shell particles (AGuIX) were reported to incorporate the chelators DOTAGA (1,4,7,10-tetraazacyclododecane-1-glutaric anhydride-4,7,10-triaceic acid) and NODAGA (2,2’-(7-(1-carboxy-4-((2,5-dioxopyrrolidin-1-yl)oxy)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid), for Gd$^{3+}$ coordination as MR imaging reporter and for Ga$^{3+}$ radiolabelling as PET reporter, respectively [85]. In vivo MR imaging showed that the high r1 relaxivity of the bimodal nanoparticles led to signal enhancement in the kidneys. The extremely small and monodisperse nanoparticles with several Gd and $^{68}$Ga ions on their surface could be cleared by renal excretion. Signal co-localization from PET and MR imaging confirmed the nanoparticle elimination pattern. The top-down synthetic approach was used for preparing bimodal nanoparticles [86]. Firstly, the gadolinium oxide Gd$_2$O$_3$ core was synthesized and coated with a polysiloxane shell. Then, the resulting Gd$_2$O$_3$-SiO$_x$ core-shell particles were encapsulated with DOTAGA chelator. Finally, free Gd$^{3+}$ dissociated from the Gd$_2$O$_3$ core chelate to DOTAGA. The dissolution of the core resulted in fragmentation of the nanoparticles into SRPs of polysiloxane. DTPA was introduced via transmetallation of Gd$^{3+}$ from NODAGA, which would offer radiolabelling (Figure 14). The nanoparticle composition was fully characterized. The rigid structure of SRPs led to substantial contrast enhancement for MR. These SRPs
can be further conjugated with Cy5.5 fluorophores as trimodal probes for MR, PET/SPECT, and fluorescence imaging [87].

Liposomes (LPs) have been used as a carrier system to deliver tumor-targeting antibody or peptide for cancer treatment or therapy [88, 89]. By incorporating paramagnetic gadolinium and then labeling with radionuclides such as $^{166}$Ho or $^{99m}$Tc, liposomes can be used as bimodal SPECT-MR imaging probes. Nano-sized LPs co-loaded with gadolinium-acetylacetonate (GdAcAc) and radiolabeled with $^{166}$Ho-DTPA (GdAcAc-DTPA-Ho) proved to be a very promising multimodal imaging probe for therapy applications [90]. Novel $^{89}$Zr-radiolabeled paramagnetic LPs conjugated with octreotide were developed as PET-MR probes for imaging somatostatin receptor subtype 2 (SSTr2) targeting neuroendocrine tumors [91]. Long-circulating PEGylated LP was used for evaluation of in vitro and in vivo specific SSTr2 recognition through OCT conjugation. Direct $^{89}$Zr-radiolabeling without chelator was achieved (Figure 15). Tracking of a long-circulating dual PET-MR probe was demonstrated. At 50 h post-injection, co-registered PET-MR imaging showed clear tumor identification. SSTr2 tumor-specific contrast by octreotide-liposome (OL) was highlighted compared to control-liposome (CL).

EP-2104R is a fibrin-targeting Gd-based MR CA in which a six amino-acid cyclic peptide is conjugated to four Gd(DOTA) chelates [92]. EP-2104R was partially depleted of Gd$^{3+}$ by DTPA ligand and then chelated with $^{64}$Cu to make a fibrin-targeting dual PET-MR probe for simultaneous PET and MR imaging of thrombus [93]. The thrombus in a rat arterial thrombus model was clearly identified with both PET and MR images [94]. Lipophilic Gd(DTPA) was incorporated into the outer phospholipid layer of the integrin $\alpha_v\beta_3$-targeted $^{99m}$Tc nanoparticles to make a SPECT-MR imaging probe for tumor angiogenesis with 3D neovascular mapping [95]. In vivo studies showed that initial treatment of $\alpha_v\beta_3$-targeted $^{99m}$Tc-gadolinium nanoparticles weakens MR contrast enhancement in neovascular imaging. Tumor angiogenesis was characterized by $\alpha_v\beta_3$-targeted paramagnetic nanoparticles with MR functionality and $^{99m}$Tc labelling in a Vx2 model for SPECT-CT acquisition.

**Small molecular trimodal probes**

Trimodal imaging has emerged as a novel imaging strategy for translational research, which combines three different modalities together such as PET/SPECT-MR-Optical to provide complementary information and achieve synergistic advantages over any single modality alone. The main challenge of trimodal imaging lies in developing an efficient platform that incorporates various imaging modality reporters without disturbing each other while maintaining the entity intact. Photoacoustic tomography (PAT) provides high-resolution functional and molecular optical imaging with remarkably increased imaging depth by using the
molecules in which paramagnetic metallo-porphyrins porphyrin macrocycles as fluorescence reporters. The radiolabeled with 99mTc and 111In porphyrins as were coordinated with Gd as MRI CA and SPECT tracer were reported as bimodal imaging respectively.

photoacoustic effect of light absorbers compared with traditional optical imaging [96]. Nanoparticles and melanin have been used as exogeneous and intrinsic contrast agents for functional and molecular PAT, respectively.

A single small molecule is unlikely to be designed as a trimodal imaging probe due to its limited loading capacity. Only one example of a proposed trimodal PET-MR-fluorescence imaging probe in a single small molecule has been reported (Figure 16) [97]. Gd(DO3A-AM)-Cu(porphyrin) is comprised of Gd3+-chelated tetraazacycloalkane Gd(DO3A-AM) as MRI CA, a free-base porphyrin for 64Cu complex Cu(porphyrin) as a PET tracer and porphyrin macrocycles as fluorescence reporters. The molecules in which paramagnetic metallo-porphyrins were coordinated with Gd as MRI CA and radiolabeled with 99mTc and 111In porphyrins as SPECT tracer were reported as bimodal imaging probes for tumor imaging due to their preferential tumor uptake [98, 99]. The water-soluble hetero-bimetallic coordination conjugate was facilely synthesized using an efficient synthetic strategy in which Gd3+ and Cu2+ coordinated to their respective chelators, forming a strong complex to avoid trans-chelation or trans-metalation at physiological pH. The trimodal ligand can be further modified or functional groups introduced for biological applications.

**Nano-sized trimodal probes**

To design PET-MR trimodality imaging probes, the nano-structures should have enough surface area to offer several conjugation sites for labeling three imaging modality reporters and other functionalities. Table 3 summarizes recently developed trimodal PET-MR and SPECT-MR probes.

![Figure 16. Small molecule trimodal probe. Adapted with permission from [97], copyright 2011 Royal Society of Chemistry.](http://www.thno.org)

**Table 3. Trimodal probes and their applications.**

| Probe | PET(SPECT) reporter | MR reporter | Third imaging reporter | Applications | Ref. |
|-------|---------------------|-------------|------------------------|--------------|-----|
| Gd(DO3A-AM)-64Cu(Porphyrin) | 64Cu | Gd-DOTA | Porphyrin fluorescence | Potential trimodal imaging | 97 |
| 64Cu-Apoferretin (APF) | 64Cu | APF/Fe3+ | Fe3+ and APF | HT29 tumor targeting | 101 |
| 111In-DTPA-CLIO-Tat-FTIC | 111In | SPION | FITC | Tracking and recovery of progenitor cells | 102 |
| 64Ga-HIV-1-tat-FTIC peptide and 111In-HIV-1-tat-FTIC peptide | 64Ga & 111In | SPION | FITC | Hepatogenic HuH7 cells labeling | 105 |
| 64Cu-DOTA-HSA-IONP-Cy5.5 | 64Cu | SPION | Cy5.5 | Good retention rate and a high extravasation rate at tumor | 106 |
| 124I-TCL-SPIONs | 124I | SPION | Cy5.5 | SLN imaging | 107 |
| 64Ga-SPION | 64Ga | SPION | Ga Cherenkov optical | SLN imaging | 108 |
| 64Ga-MNP/IS613(RET)-PEG/NH2-AS1411 | 64Ga | CoFeOx | NiR797 fluorescence | SLN imaging | 109 |
| 64Cu-NOTA-Au-IONP-Affibody | 64Cu | SPION | RITC fluorescence | Tracking cancer cells | 112 |
| 64Cu-Fe2-Ga-PEG | 64Cu | Fe3+ | Plasmonic Au | Targeting EGFR-positive tumor | 116 |
| 64Cu-DOTA-GdVO4%Eu-DGEA | 64Cu | GdVO4 | Eu-doped | Photothermal therapy | 117 |
| 64Cu-DOTA-MSN-Gd-DTTA-FTIC | 64Cu | Gd-DTTA | FTIC fluorescence | Conjugate with Asp-Gly-Glu-Ala (DGEA) peptide for integrin αvβ3 targeted | 121 |
| 64F-NaYF4:Ga3+/Yb3+/Er3+ | 64F | Ga3+ doping NaYF4 | Yb3+/Er3+ co-doped UCL imaging | Mapping of SLNs and tumor metastases | 122 |
| 124I-(cRGDykk2)-NaGdF4:EYb3+/Eu3+ | 124I | NaGdF4 & Eu3+ | Yb3+/Er3+ co-doped UCL imaging | Cellular scale to whole-body imaging of small animal | 123 |
| 18F/64Cu-Cu15Fe22O3@NaYF4:Yb3+/Er3+-BP-PEG | 18F & 64Cu | Cu15Fe22O3 | Yb3+/Er3+ co-doped UCL imaging | αvβ3 integrin-expressing U87MG tumor cells and xenografted tumor models | 124 |
| | | | | SLN imaging | |
Melanin, oxidation from tyrosine, is a functional biomarker for melanoma imaging due to its abundance in melanotic melanomas. Interestingly, water-soluble melanin nanoparticles (MNPs) were reported as a multifunctional nanoplatform for PET-MR-photoacoustic imaging (PAI) \(^\text{[100]}\). The advantages of MNPs include their intrinsic PAI characteristics and natural binding ability with metal ions such as \(64\text{Cu}^{2+}\) and \(\text{Fe}^{3+}\), which could skip the complicated chelator conjugation. With further conjugation with cyclic \((\text{RGDFC})\) peptide for \(\alpha_\text{v}\beta_3\) integrin targeting, MNPs showed high accumulation in U87MG tumor by the enhanced permeability and retention effect (EPR). However, the disadvantages of melanin multifunctional nanoplatforms such as their poor water-solubility, melanin aggregation into polymer, and metal ions-initiated precipitation need to be overcome for their further theranostic applications. Apoferritin was used as a nanoplatform to embed MNPs into its cavity as a trimodal imaging probe for efficient cancer targeting because of its transferrin receptors 1-targeting ability \(^\text{[101]}\). MNP as a trimodal imaging PET-MR-PAT nanoplatform showed it can be applied to imaging of diseased tissues at different depths with molecular and anatomical information. It can also serve as a platform for guiding tumor resection, in which PAI is used to localize the superficial and relatively deep tumors in surgery. The results indicated that MNP is promising for theranostic applications.

Functional SPIO nanoparticles meet the requirements to label PET/SPECT isotopes at conjugation sites, to attach functional groups as optical/NIR fluorescence imaging reporters, and even to conjugate targeting groups with receptor-binding affinity. One pioneering work on functional SPIO nanoparticles as trimodal imaging probes is the novel trimodal SPIO nanoparticle CLIO-Tat, which consists of a monocristalline MR-active \(\text{Fe}_3\text{O}_4\) core (5 nm) stabilized by an aminated polysaccharide coating (45 nm) for \(\text{in vivo}\) tracking of progenitor cells \(^\text{[102]}\) (\text{Figure 18}\). The dextran coating was attached to lysine moieties of FITC-derivative Tat peptide for fluorescence imaging and also conjugated with DTPA chelator to label with \(^{111}\text{In}\) for SPECT imaging. The probe could be used efficiently for \(\text{in vivo}\) tracking of the distribution and differentiation of progenitor and stem cells by the three imaging techniques. A similar strategy was developed by the same group to synthesize a new trimodal probe \(64\text{Cu}-\text{TNP}\) for imaging macrophages in inflammatory atherosclerotic plaques \(^\text{[103]}\). The aminated polysaccharide coating was used to optimize the biocompatibility, to extend the blood half-life, to attach the \(64\text{Cu}\)-labeled-DTPA for PET imaging and to conjugate fluorochrome for near-infrared imaging. \text{In vivo}\ PET studies on apoE\text{-/}/mice demonstrated higher uptake and longer persistence in the aortic arch for \(64\text{Cu}\)-TNP than for \(^{18}\text{FDG}\) \(^\text{[104]}\), which is consistent with fluorescence microscopy studies. The result indicated that microscopic tracer distribution could be evaluated for \(64\text{Cu}\)-TNP due to its higher radioactive signal in the aortic arch, an area of frequent inflammatory atherosclerotic plaques. Using aminosilane to modify the coating of SPIOs provided amino-reactive moieties, which have a positive charge and thus are favourable for linking with the fluorescent dye fluorescein isothiocyanate for cell tracking \text{in vivo}\ \(^\text{[105]}\).
Dopamine was used to modify the surface of SPIO nanoparticles to increase their hydrophilicity so that the modified nanoparticles could be easily encapsulated into human serum albumin (HSA) matrices [106]. This approach of encapsulation by HSA is similar to that of encapsulation of drug molecules or drug loading. The resulting HSA-IONPs were conjugated with ⁶⁴Cu-DOTA chelates and labeled with the fluorophore Cy5.5 as a trimodal PET-MR-NIRF probe for imaging the U87MG xenograft mouse model. To assess the pharmacokinetics of the probe and its preclinical applications, PET-MR-NIRF tri-modal imaging studies were performed through in vivo, ex vivo, and histological examinations. The HSA-IONPs demonstrated a long blood half-life and considerable tumor retention due to EPR. The in vivo studies showed that decomposition of HSA coating from the particle surface may occur, but the investigations using ex vivo fluorescence demonstrated that no substantial detached HSA was found. The results of this study indicated that the particles can be used as nanosystems for co-loading drug molecules, such as paclitaxel (PTX), for theranostic applications. Moreover, the HSA coating layer could enhance electrostatic interaction of the particles with drug molecules.

A very interesting approach for the preparation of a PET-MR-optical trimodal imaging probe is that of ¹²⁴I radioisotope conjugation to SPIO nanoparticles. The trimodal nanoparticles exhibited a long half-life of 4.2 days. Their emission of high-energy positron decay with a β⁺ mean energy of 819 keV led to strong Cerenkov radiation as an optical imaging reporter in which no fluorescent dye is needed, unlike in the case of previously described trimodal imaging reporters (Figure 19) [107]. SPION with cross-linked polymer coating layers containing PEG (TCL-SPION) was selected as an MR imaging reporter. ¹²⁴I was labeled at the ortho-position of the phenol ring in tyramine (4-(2-aminoethyl)pheno) that modified the coating of Fe₃O₄ magnetite nanoparticles to provide tyramine-conjugated TCL-SPIONs. The optimal particle size, high in vivo stability and anti-biofouling characteristics of TCL-SPIONs were suitable for SLN imaging. The ¹²⁴I-labeled TCL-SPIONs were injected into both front paws of a 4T1 tumor-bearing BALB/c mouse. Cerenkov imaging, microPET and MR imaging consistently demonstrated a lower accumulation of ¹²⁴I-labeled TCL-SPIONs in the left brachial SLN, while LN could be more accurately visualized in optical images than in the other two modality images. The lower uptake of the probe in the left brachial SLN that is close to the implanted 4T1 tumor was because of metastasis of the tumor cells into the LN, resulting in its dysfunction. Consistent results were also found in the ex vivo optical and microPET images of the dissected LNs. Similar to ¹²⁴I radioisotope, ⁶⁸Ga enables Cerenkov radiation that can be used as an optical imaging reporter. A single dose of ⁶⁸Ga-SPIONs was reported as a PET-MR-Cerenkov trimodal probe for imaging and biodistribution study of SLNs [108].

MNP-SiO₂(NIR797), magnetic silica nanoparticle encapsulating NIRF dye in a silica shell, was reported as a trimodal PET-MR-NIRF probe for in vivo imaging of the SLN in mice [109]. Due to encapsulation of NIR797 dye in a rigid silica matrix, enhanced fluorescence signal intensity and improved photostability of MNP-SiO₂(NIR797) were found. The probe was used to visualize cells in the deep tissue by enhanced NIR fluorescence imaging. When the
chelator NOTA was covalently conjugated to the surface of MNP-SiO₂(NIR797) and radiolabeled with a radioisotope ⁶⁸Ga, the fluorescence intensity and stability of the resulting ⁶⁸Ga-[MNP-SiO₂(NIR797)] did not change significantly. T₂ relaxivity measurements on different magnetic field MR systems showed that radiolabeling of ⁶⁸Ga did not interfere with the magnetic characteristics. For Gd-chelated macromolecule MR contrast agents, the particle size of G₆ dendrimers (~9 nm) was more suitable for detection of LN than the particle sizes of G₈ (~12 nm) or G₄ (~6 nm) dendrimers [110]. For silica nanoparticles, the size of 40 nm among several particle sizes was reported to have an ideal distribution profile in lymphatics [111]. Nanoparticles with particle size 45 ± 6 nm were selected for SLN imaging as they were optimal for entering the lymphatic vessels and retaining in the capillary vessels within the lymphatics. The trimodal tracer was injected into the forepaw of mice for SLN mapping using PET, MR and NIRF. When 100 µg of ⁶⁸Ga-[MNP-SiO₂(NIR797)] was subcutaneously injected, PET images of axillary and brachial LNs and clear signals of NIFR in axillary and brachial LNs could be obtained, but MR images in axillary LNs were detected only at doses higher than 200 µg of ⁶⁸Ga-[MNP-SiO₂(NIR797)]. The strong fluorescence signal indicated that it could provide real-time NIRF imaging for intra-operative guidance. Similarly, encapsulation of fluorescent rhodamine with AS1411 aptamer, which targets nucleolin protein in cancer cells, in a silica matrix of cobalt-ferrite magnetic nanoparticles was conjugated to ⁶⁸Ga-labeled chelate for tracking cancer cells by in vitro and in vivo multimodal imaging techniques [112].

Unlike most PET-MR or multimodal probes, which have only one single component of SPIO nanoparticles, dumbbell-like NPs (DBNPs) have two different NPs within one nanostructure. The advantages of dumbbell nanostructure are that it offers different NP surfaces for coupling of several biological targeting moieties, drug molecules, or labeling imaging reporters for its applications in diagnosis and therapy that overcome the limitation of single component NP such as low yield of conjugating different ligands simultaneously, intimate interference of functional groups, complex imaging reporters labeling or modification, and poorer performance for in vivo investigations [113-115]. A highly monodisperse dumbbell-shaped AuIONP with a plasmonic Au as an optical imaging reporter was developed as a trimodal PET-MR-optical probe for cancer imaging [116]. The hetero-nanostructures have optimal physicochemical parameters such as size, shape, highly monodisperse characteristics and surface modification capability for application in tumor cell detection. In order to enhance the in vivo targeting ability of the nanoprobe toward epidermal growth factor receptor (EGFR)-positive tumors, affibody molecules were conjugated to the IO surface via PEG linkers and the Au component was surface-specifically modified with thiolated PEG.

Figure 19. Triple-modality imaging of radiolabeled nanoparticles: a) optical, b) microPET, and c) MRI of ¹²⁴I-labeled SPIONs injected into the front paws of a BALB/c mouse bearing a 4T1 tumor implanted on its shoulder. Tumor: yellow arrow; sentinel lymph node: red dotted circle; injection site: “I”; bladder: red arrow; fiduciary markers: white arrow head. d) Ex vivo luminescence (top) and microPET (bottom) images of the dissected lymph nodes. e) Schematic diagram of the tumor metastasis model and injection route of radiolabeled nanoparticles. Adapted with permission from [107], copyright 2010 Wiley-VCH.
linkers to conjugate chelator NOTA, then radiolabeled with $^{64}\text{Cu}$, resulting in an EGFR-targeting PET-MR-optical imaging probe, $^{64}\text{Cu}$-NOTA-Au-IONP-Affibody. In vitro rapid cell uptake of $^{64}\text{Cu}$-NOTA-Au-IONP-Affibody in A431 cells showed high specificity for binding with EGFR positive cells. In vivo MR and PET imaging studies showed higher tumor accumulation of the nanoprobe, indicating its specific targeting to EGFR-expressing cells and tumor. The results indicated that the nanoplatform could be promising for conjugation with various types of biomolecules for cancer targeting or drug delivery through surface modifications.

Only one example of chelator-free radiolabeling of $^{64}\text{Cu}$ to ultra-small iron-gallic acid coordination polymer nanoparticles as a trimodal probe has been reported [117]. In vivo MR and PAT bimodal imaging studies demonstrated passive tumor targeting of the PEGylated iron-gallic acid coordination polymer nanoparticles (Fe-Ga-PEG CPNs). Fe-Ga-PEG CPNs were used for further in vivo photothermal therapy. The $^{64}\text{Cu}$-radiolabeled Fe-Ga-PEG enabled in vivo PET imaging. The straightforward preparation and biocompatible characteristics of the trimodal probe indicated its promising theranostic application.

Besides SPIO-based nanoparticles, lanthanide-rich nanoparticles such as lanthanide-co-doped NaYF$_4$ nanophosphors are another class of nanostructures recently developed as multimodal imaging probes. By doping Gd$^{3+}$, Yb$^{3+}$, and Er$^{3+}$ into NaYF$_4$, the resulting nanocrystals of Gd$^{3+}$/Yb$^{3+}$/Er$^{3+}$ co-doped NaYF$_4$ can be used as bimodal MR-luminescent imaging probe due to the unique magnetic and luminescent properties of these lanthanide ions [118-120]. A PET-MR-fluorescence imaging probe for targeting integrin $\alpha_\nu\beta_3$ was composed of $^{64}\text{Cu}$-labeled Eu$^{3+}$-doped GdVO$_4$ conjugated with Asp-Gly-Glu-Ala (DGEA) peptides, forming two-dimensional nanosheets [121]. The oleic acid (OA)-coated Eu$^{3+}$-doped GdVO$_4$ nanosheets were prepared by a solvothermal reaction, then OA was replaced by polyacrylic acid (PAA) via ligand exchange to improve the biocompatibility. The resulting carboxyl-functionalyzed nanosheets were further conjugated with DOTA for $^{64}\text{Cu}$ labeling and with DGEA for integrin $\alpha_\nu\beta_3$ targeting. In vitro fluorescence imaging and in vivo MR and micro-PET imaging studies in a small animal prostate cancer model of $^{64}\text{Cu}$-labeled Eu$^{3+}$-doped GdVO$_4$ nanosheets demonstrated their good optical property, T1-weighted MR signal enhancement and integrin $\alpha_\nu\beta_3$ targeting. A mesoporous silica-based trimodal imaging nanoprobe (MSN-probe), which is comprised of three imaging reporters including NIR dye ZW800, T1 MR contrast agent Gd$^{3+}$ and PET radionuclide $^{64}\text{Cu}$ coordinated to chelators in a mesoporous silica-based nanoparticle via various conjugation steps, was reported to accomplish long-term in vivo SLNs imaging [122]. Due to its high stability and intracellular retention, accumulation of the nanoprobe in metastatic T-SLNs and normal contra-lateral SLNs (N-SLNs) in a 4T1 tumor metastasis model could be distinguished.

$^{18}\text{F}$-labeled lanthanide nanocrystals of Gd$^{3+}$/Yb$^{3+}$/Er$^{3+}$ co-doped NaYF$_4$ was developed for trimodal PET-MR-optical imaging in which lanthanide-doped nanocrystals provide MR and luminescence imaging reporters, while $^{18}\text{F}$ radiolabeling simultaneously enables PET imaging [123]. Hydrophobic OA-coated NaY$_{0.2}$Gd$_{0.6}$Yb$_{0.18}$Er$_{0.02}$F$_4$ nanophosphors (OA-NPs) were replaced by hydrophilic citrate-capping (cit-NPs) through ligand exchange of OA with citrate. $^{18}\text{F}$-radiolabeling was achieved by a reaction through the strong binding between Y$^{3+}$ and $^{18}\text{F}$. RGD peptide-functionalized Yb$^{3+}$/Er$^{3+}$ co-doped NaGdF$_4$ upconversion nanophosphors (UCNPs) were employed as a trimodal probe for tumor angiogenesis imaging [124]. The octalamine-modified polyacrylic acid polymer coating was replaced with PEG polymers and conjugated with dimeric cyclic RGD peptides (cRGDyk)$_2$ to increase the specific binding ability. The resulting (cRGDyk)$_2$-conjugated nanophosphors were radiolabeled with $^{124}\text{I}$ at the tyrosine moiety of (cRGDyk)$_2$ peptides through a radiiodination method (Figure 20). RGD peptides specifically bind to $\alpha_\nu\beta_3$ integrin, which is overexpressed in many types of cancer and vasculature. RGD-functionalized UCNPs $^{124}$I-(cRGDyk)$_2$-UCNPs were reported as an integrin-positive U87MG tumor-specific targeted trimodal probe. Specific localization of (cRGDyk)$_2$-UCNPs on the surface of U87MG cells by luminescence imaging, positive T1 contrast enhancement in U87MG tumors by MRI and specific uptake of $^{124}$I-(cRGDyk)$_2$-UCNPs in U87MG tumors by PET demonstrated that the probe can be used in trimodal imaging for cancer-specific diagnosis. Although the preliminary in vitro cellular cytotoxicity of (cRGDyk)$_2$-UCNPs was low, in vivo toxicity including histological and metabolic toxic effects needs to be established. Potential toxicity of unchelated lanthanide-containing nanoparticles remains an obstruction for their further applications in preclinical and clinical investigations.

Fabrication of hybrid inorganic nanocomposites, which contain two or more components for multimodal imaging reporters, is a novel approach to synthesize multimodal imaging probes. SPIOs such as Fe$_3$O$_4$ have been used as a MR imaging reporter, while
lanthanide-rich nanomaterials such as NaGdF₄ or lanthanide co-doped nanophosphors represent the luminescence imaging reporter in hybrid inorganic nanoparticles. Fe₃O₄@NaGdF₄ nanoparticles [125], NaYF₄@FeₓOᵧ [126], and Fe₃O₄@LnF₃·₂₄ [127] were reported as bimodal MR and optical imaging probes. When radiolabeling with [¹⁸F]-fluoride or ⁶⁴Cu/⁹⁹mTc-bisphosphonate (BP) conjugates to Fe₃O₄@NaYF₄ core/shell nanoparticles with different cation dopants in the shell or core, the inorganic core-shell nanoparticles were applied as trimodal probes for imaging SLN [128]. Before radiolabeling, the nanoparticles were coated with BP-PEG to improve their binding to [¹⁸F]-fluoride or ⁶⁴Cu/⁹⁹mTc-bisphosphonate conjugates. High r² values and r²/r¹ ratios for T₂-weighted MRI were found for both Co₀.₁₆Fe₂.₈₄O₄@NaYF₄(Yb, Er)-BP-PEG and Fe₃O₄@NaYF₄(Yb, Tm)-BP-PEG. The metabolism from PET-MR imaging showed positively charged Fe₃O₄@NaYF₄(Yb, Tm)-BP-PEG were excreted from the blood pool faster than negatively charged Co₀.₁₆Fe₂.₈₄O₄@NaYF₄(Yb, Er)-BP-PEG. In vivo imaging studies in LNs showed obvious advantages of combining imaging modalities (Figure 21). When combined with highly sensitive PET, but not MRI alone, the in vivo imaging studies offered improved presurgical mapping of iliac and popliteal LN locations and provided more details to interpret the imaging of SLNs that are relevant to the pathology of LNs and tumor metastasis in humans. The fluorescence could offer additional information of anatomical and functional changes during surgery and subsequently during pathological examination of excised tissues.

**Discussion**

Thanks to recently available hybrid imaging techniques, the advantages of high temporal and spatial sensitivity, and the anatomical and functional information provided by both PET and MR imaging techniques can be obtained by combination of the single imaging modalities. With the injection of a multimodal probe, both the scanning time and dose can be reduced with enhanced imaging signals for diagnosis, tumor differentiation, localisation and mapping, etc. Significant differences in concentrations of the two imaging probes should be noted due to the large differences in sensitivities of the two techniques. PET tracers generally need to be injected in extremely small concentrations (pico-nano-molar range), whilst MR CAs need to be injected in millimolar range, typically in thousand-fold higher concentrations than PET tracers. This problem cannot be solved by simply adding two different classes of imaging probes together. Individual PET tracer and MR CAs could be injected simultaneously, but validation and registration problems could arise unless they have identical pharmacodynamic properties. The development of multimodal probes enables simultaneous data acquisition without validation and registration problems.

---

**Figure 20.** Synthesis scheme of ¹²⁴I-(cRGDyk)₂-UCNP conjugates. Polymer-coated UCNP (pcUCNP) was reacted both with (cRGDyk)₂ peptide and with MeO-PEG-NH₂ (molecular weight, 2,000) using EDC/N-hydroxysulfosuccinimide. Tyrosine residues of (cRGDyk)₂ were labeled with ¹²⁴I using Iodo-Beads (Pierce). Adapted with permission from [124], copyright 2013 Society of Nuclear Medicine and Molecular Imaging.
Figure 21. Lymph node PET-MRI imaging of a mouse with an inflamed right leg using 18F-labeled Fe3O4@NaYF4(Yb, Tm)-BP-PEG NPs (a-d) or with [18F]-fluoride only (e-g): (a) whole-body PET image showing uptake of radiolabeled NPs (maximum intensity projection; bone uptake was observed due to gradual release of fluoride from NPs due to the 7 h delay post injection of NPs); (b) PET image showing popliteal and iliac lymph nodes (coronal section); (c) PET-MRI fused image (coronal section); (d) MR image (coronal section) with darkening contrast inside the popliteal lymph node at left-rear (white circle) and “outside” lymph node at the inflamed right-rear (red circle) induced by injection of 30 μL 0.67 mg/mL lipopolysaccharide (LPS) 18 h prior to imaging, and at iliac lymph node; (e) PET image following injection of [18F]-fluoride showing no contrast in lymph nodes in the absence of NPs and prominent uptake by skeleton; (f) PET-MRI fused image following injection of [18F]-fluoride, showing no radioactivity associated with lymph nodes; (g) MR image showing no difference between normal popliteal lymph node at left-rear leg (white circle) and the inflamed lymph node at right-rear leg induced by injection of 30 μL 0.67 mg/mL LPS 18 h prior to imaging; and (h-k) enlarged MR images of corresponding lymph nodes. Adapted with permission from [128], copyright 2016 American Chemical Society.

Nano-structured multimodal probes have their advantages for diagnosis of tumors, SLN metastasis, and inflammatory disease, etc. Compared with nano-structures, small molecules are unlikely to be designed as multimodal imaging probes due to their limited loading capacity. Despite these limitations, small molecular probes have their applications for certain biological events such as pH-response, in which the MR reporter relaxivity is responsive to pH while the PET reporter is responsible for sensitivity and quantification. The limited loading capacity of a small molecule accounts for it being unlikely to be a carrier of trimodal imaging reporters and functionalities. There is only one example of a trimodal imaging probe reported as a proof-of-concept of this design [97]. The majority of multi-imaging modal probes are nanoparticle-based because of their large surface area for conjugation sites, targeting and therapeutic biomolecules functionalizations, and physicochemical and biological stability.

CNTs have been used as nano-carriers for diversified biomedical applications due to their characteristics such as high surface area, nanoscale tube with hollow cavity, etc [76]. By incorporating imaging probes into CNTs, CNTs are promising candidates for multimodal imaging through chemical design to improve their sensitivity, biocompatibility and pharmacokinetics for diagnostic and therapeutic applications, although their potential cytotoxicity needs to be taken into account [77-84]. Hybrid nanostructures can be formed from non-covalent functionalization either in the cavity or external attachment, for example, functionalization with phospholipid-PEG for better biocompatibility in human serum environments. The length of hybrid carbon nanotube imaging probes is crucial for their biodistribution profile. Liposomes are another class of nano-vehicles to deliver tumor-targeting antibody or peptide together with conjugated multimodal imaging reporters for cancer imaging and therapy due to their biocompatibility, high probe-to-carrier loading ratios, and straightforward encapsulation capability of both hydrophilic and hydrophobic probes [88-91]. There is a challenge to achieve precise control of loading multiple functionalities. Bioconjugation methodologies of functional groups or specific targeting moiety modifications on the surface of nanostructures without composition control could hinder their translational applications. Moreover, the synthesis methodology for preparing nanostructures as multimodal imaging probes may have its
challenges as steps in the synthesis may interfere with each other. Intramolecular interference between imaging reporters and targeting groups in a single entity may reduce its targeting capability or change the biodistribution pattern of the probe. Ferritin nanocages as a nanoplatform for multifunctional loading with precise control of their composition would be a promising way [129].

The size, shape, composition, coating, and surface properties of the nanostructures play important roles in the biodistribution of the multimodal probes. Larger particles of dextran-coated nanoparticles lead to more liver uptake. Quick uptake of SPIO nanoparticles by macrophages of the MPS could lead to short circulation times, which could hinder further conjugation with targeting moieties. PEGylation of the nanoparticle surface makes imaging probes biocompatible: the hydrophilic layer could minimize particle aggregation and MPS uptake. PEG-coating causes the nanoparticles to have a longer blood circulation time to improve uptake in LNs and increased accumulation in tumor [130]. Modification of the surface of SPIOs with dopamine could increase the hydrophilicity of nanoparticles, which is favourable for encapsulation into HSA matrices [106]. Cell viability studies showed that most of radiolabeled SPIOs and other multimodal imaging probes did not have cellular toxicity in a variety of cell lines. However, the in vivo toxicity profiles of imaging probes through a well-designed toxicity test need to be established for preclinical investigations and before clinical trials.

The size of nanostructures is one of the most important factors for the biodistribution pattern of the imaging probe. For nanoparticles, a small hydrodynamic size (less than 100 nm) and low zeta potential have an important effect on controlling circulation time. Avoiding immediate MPS clearance is favourable for targeting applications [131]. The accumulation of 100 nm particles in the MPS was much higher compared with larger particles [132]. Smaller particles had much higher and faster uptake in the target of interest, while larger nanoparticles transported more slowly to the target [128]. Smaller particles also have higher tumor uptake [133,134], and the multimodal probe could be made as small as possible for tumor targeting.

The majority of radiometals suitable for PET/SPECT imaging and therapy applications need a chelator to form stable complexes [135]. A specific coordination chelator has been employed for each particular radiometal based on its physicochemical properties such as oxidation state, coordination number, kinetic inerterness, etc. The chelator also has its second function to covalently bind to the targeting moiety of the probe for its biological applications, defined as bifunctional characteristics. The transition metals such as ⁶⁴Cu, ⁶⁸Ga, ⁹⁹mTc form tetradentate to hexadentate chelates, as commonly seen in radiopharmaceuticals, while the lanthanides such as Gd³⁺ tend to form eight to nine coordination complexes for T₁-weighted MRI contrast agents. Although the well-established radiometal chelation is the common radiochemical method to label nanoparticles, there are some shortcomings such as unfavorable radiolabeling conditions [136], and transchelation of radiometal to proteins leading to high uptake in nontargeted organs and further misinterpretation of PET images [137-139]. Chelator-free and core-doped radiolabeling are new approaches to radiolabel nanoparticles with (1) improved stability, which is critical for diagnostic accuracy, (2) increased radiolabeling yield by straightforward attachment of radionuclides to the nanoparticle surface or incorporation into the particle core, and (3) better in vivo performance due to no transchelation of radiometal for misinterpretation of PET images and non-necessary radiation burden. However, the chelator-free and core-doped approaches lack general labeling procedures. Radiolabeling usually occurs before nanoparticle fabrication, which is another drawback. As such, incorporation of the radiometals during nanoparticle fabrication is not feasible for many short-lived radionuclides such as ⁶⁸Ga [140]. Core-doping radiolabels during nanoparticle synthesis represents a general strategy for incorporating different metal radionuclides, but it needs full preparation and characterization of the entire nanoparticle for each radiosynthesis.

One of the key applications for multimodal imaging probes is to develop a probe by molecular design with targeting capability such as tumor, SLNs and fibrin targeting. By surface modifications or conjugation with targeting biomolecules, radiolabeled SPIO nanoparticles can be developed as targeted multimodal imaging probes, targeting, for example, hepatocytes with lactobionic acid [54], macrophages with maleic anhydride [55, 56], HT-29 cancer cells with oleinolic acid [57], prostate specific membrane antigen with glutamate-urea-lysine [58], MUC-1-positive breast cancer cells with monoclonal antibody C595 mAb [59], and fibrin for imaging of thrombus [92-94].

A variety of nanostructures have been used for imaging of cancer and therapy. Tumor uptake of imaging probe is either through EPR to tumor in a passive way or transport of nanoscale hydrophilic biomolecules via endocytosis for cellular internalization [141,142]. RGD has been chosen
extensively for preparing multimodal imaging probes due to its high affinity to tumor via integrin αvβ3 expression [51-57]. The tumor-targeting peptide 64Cu-DOTA-IO-RGD is noted for having the highest in vivo tumor uptake (10.1 ± 2.1 %ID/g at 4 h post injection) among other targeting biomolecules. SPIOs radiolabeled with 64Cu or 68Ga and conjugated with engineered mAb also showed high tumor uptake. However, in some cases, in vivo targeting ability would be affected due to coverage of the targeting sites by protein corona [59].

Surgical removal of SLNs is an effective way to prevent tumor metastasis via the lymphatic system. SPIO nanoparticles have been used to detect SLNs with high spatial resolution [143]. However, using MRI only could lead to issues of quantification of probes with low specificity. So, adding a radiolabeled nuclide to SPIOs for combining high-sensitivity PET/SPECT with high-resolution MR to detect SLNs would be more accurate and could be quantified. Radiolabeled SPIOs as bimodal probes were reported for potential clinical applications in the preoperative localization and characterization of SLNs [41,42, 107,108]. Magnetic silica nanoparticles encapsulating NIRF dye in a silica shell MNP-SiO2(NIR797) is another class of multimodal probe for in vivo imaging of the SLN with enhanced fluorescence signal intensity and improved photostability due to encapsulation of NIR797 dye in a rigid silica matrix [109-112]. But, these reported imaging probes have only been used in preclinical proof-of-concept studies. No clinical trial data has been obtained.

**Conclusions**

The goal of PET-MR and SPECT-MR multimodal probe development is to develop probes that have the following characteristics: high temporal and spatial sensitivity, anatomical and functional resolution, optimal biodistribution and pharmacokinetic profiles and specific targeting to the tissue of interest. The demand for new PET-MR and SPECT-MR multimodal probes is expected to increase to achieve these goals. There is a unique need to develop PET-MR and SPECT-MR multimodal probes for accurate diagnosis. The present review provides a comprehensive overview of all reported PET-MR and SPECT-MR multimodal probes including small molecule bimodal probes, nano-sized bimodal probes, small molecule trimodal probes and nano-sized trimodal imaging probes. The development of bimodal probes has advantages for simultaneous data acquisition and mapping of probes across resolution scales. The design and methodology of bimodal probes would result in various biological applications such as diagnosis of tumors, SLN metastases, and inflammatory disease, etc. Through this comprehensive review, we aim to overview the current development of PET-MR and PET-SPECT bimodality probes in this new emerging field. Some multimodal probes can be extended to theranostic applications such as melanin nanoparticle (MNP) trimodal PET-MR-PAT probes. We believe more and more theranostic probes will be developed. Their novel synthetic methodologies, biocompatibility and potential applications, especially for tumor and SLNs have been surveyed, whereas the challenges as well as limitations of multimodal probes have been discussed. This review could provide some future research directions to those who have expertise in bio-imaging research such as medicinal chemistry and radiochemistry, PET/SPECT-MR physics, biology, radiology and biomedical imaging engineering.

**Abbreviations**

BP: bisphosphonate; CA: contrast agent; CL: control-liposome; CN: carbon nanotube; CPN: coordination polymer nanoparticle; CT: computed tomography; DBNP: dumbbell-like nanoparticle; DGEA: Asp-Gly-Glu-Ala peptide; DFO: deferoxoxamine; DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; DOTAGA: 1,4,7,10-tetraazacyclododecane-1-glutaric anhydride-4,7,10-triacetic acid; DPA: dipicolylamine-alendronate; DTCBP: dithiocarbamate bisphosphonates; DTPA: diethylenetriamine-pentaacetic acid; EGFR: epidermal growth factor receptor; EPR: enhanced permeability and retention effect; FDA: food and drug administration; FDG: fluorodeoxyglucose; FH: ferahem; FMRI: functional magnetic resonance imaging; HSA: human serum albumin; IO: iron oxide; LN: lymph node; LP: liposome; mAbMB: anti-mesothelin antibody; MAL: maleimide; MNP: melanin nanoparticle; MPS: mononuclear phagocyte system; MR: magnetic resonance; MRI: magnetic resonance imaging; MRS: magnetic resonance spectroscopy; MWNT: multi-walled carbon nanotube; NIR: near infrared; NODAGA: (2,2'-(7-(1-carboxy-4-(2,5-dioxopyrrolidin-1-yl)oxy)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid; NOTA: 1,4,7-Triazacyclononane-1,4,7-triacetic acid; OL: ocreotide-liposome; OA: oleic acid; PAA: poly(acrylic acid); PAI: photoacoustic imaging; PASP: polyaspartic acid; PAT: photoacoustic tomography; PEG: poly(ethylene glycol); PET: positron emission tomography; PTX: paclitaxel; RGD: cyclic arginine-glycine-aspartic; RF: radiofrequency; SA: serum albumin; SCN-Bz: S-2-(4-isothiocyanatobenzyl); SLN: sentinel lymph node; SPECT: single photon emission computed tomography.
SPIO: superparamagnetic iron oxide; SRP: small and rigid platform; SST2: somatostatin receptor subtype 2; UCL: upconversion luminescence; UNCP: upconversion nanoporphor; USPIO: ultrasmall superparamagnetic iron oxide.

Acknowledgements
Authors acknowledge the support from Lee Kong Chian School of Medicine, Nanyang Technological University Singapore (NTU) Start-Up Grant, Singapore and NTU Austrian Institute of Technology & Medical University of Vienna internal grant (NAM/15005), Singapore.

Competing Interests
The authors have declared that no competing interest exists.

References
1. Munkoff DA. A definition of molecular imaging. J Nucl Med. 2007; 48(N): 18-21.
2. Markus R. Molecular imaging: basic principles and applications in biomedical research: World Scientific. 2013.
3. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biomedical processes in a new light. Genes Dev. 2003; 17: 545-80.
4. Louie A. Multimodality imaging probes: designs and challenges. Chem Rev. 2010; 110: 3146-95.
5. Masters BR. Molecular Fluorescence: Principles and Applications. J Biomed Opt. 2013; 18: 039901.
6. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A. 2000; 97: 9226-33.
7. Paans AMJ, van Waarde A, Elsinga PH, Willerssen ATM, Vlaar BW. Positron emission tomography: the conceptual idea using a multimodal approach. Methods. 2002; 27: 195-207.
8. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000; 41: 1369-79.
9. Merbach AS, Helm L, Toth E. The chemistry of contrast agents in medical magnetic resonance imaging: John Wiley & Sons. 2013.
10. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications. Chem Rev. 1999; 99: 2293-352.
11. Aime S, Botta M, Terreno E. Gd(III)-based contrast agents for MRI. Adv Inorg Chem. 2015; 78: 1017-32.
12. Paans AM, van Waarde A, Elsinga PH, Willerssen ATM, Vlaar BW. Positron emission tomography: the conceptual idea using a multimodal approach. Methods. 2002; 27: 195-207.
13. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000; 41: 1369-79.
14. Alessio AM, Kinahan PE, Cheng PM, Vesselle H, Karp JS. PET/CT scanner instrumentation, challenges, and solutions. Radiol Clin North Am. 2004; 42(vii): 1017-32.
15. Bulte JW, Kraitchman DL. Monitoring cell therapy using iron oxide MR contrast agents. Curr Pharm Biotechnol. 2004; 5: 567-84.
16. Gygi J, Schoppet M, Tschumi AO, Schmid P, Meinzer H, Wiesmann D. Multimodal imaging with contrast agents: past, present and future. Eur Radiol. 2008; 18: 1195-1203.
17. Jacob RE, Cherry SR. Complementary emerging techniques: high-resolution PET and MRI. Curr Opin Neurobiol. 2011; 21: 621-8.
18. Pichler BJ, Kolb A, Nagele T, Schlemmer HP. PET/CT: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010; 51: 133-6.
19. Jennings LE, Long NJ. ‘Two is better than one’ – probes for dual-modality molecular imaging. Chem comm. 2009; 3511-24.
20. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008; 49 Suppl 2: 1138-285.
21. Seltz O, Wangler B, Schirrmacher R, Wangler C. Biodistribution probe for combined PET and SPECT in a rodent model. J Nucl Med. 2008; 49 Suppl 2: 1138-285.
22. Bouzas O, Psomas D, Tsotakos T, Stamopoulos D, Tsoukalas C. Radiolabeled iron oxide nanoparticles as dual-modality SPECT/MRI and PET/MRI agents. Curr Top Med Chem. 2012; 12: 2094-702.
23. de Rosales RT. Potential clinical applications of bimodal PET-MRI or SPECT-MRI agents. J Labelled Comp Radiopharm. 2014; 57: 298-303.
24. Lahooti A, Sarkar S, Laurent S, Shanihazadeh S. Dual nano-sized contrast agents in PET/MRI: a systematic review. Contrast Media Mol Imaging. 2016; 11: 428-47.
25. Frullano L, Catana C, Benner T, Sherry AD, Caravan P. Bimodal MR-PET agent for quantitative pH imaging. Angew Chem Int Ed. 2010; 49: 2382-4.
Theranostics 2018, Vol. 8, Issue 22

51. de Rosales RTM, Tavaré R, Glaria A, Varma G, Protti A, Blower PJ, et al. 99mTc-bisphosphonate-iron oxide nanoparticles conjugates for dual-modality biomedical imaging. Bioconjugate Chem. 2011; 22: 455-65.

52. Sandim I, Karadzić A, Protti A, Menzaos LK, Cui Y, Yan Y, et al. Bisphosphonate-anchored PEMylation and radiolabeling of superparamagnetic iron oxide: long-circulating nanoparticles for in vivo multimodal (1T MRI/SPECT) imaging. ACS Nano. 2013; 7: 500-12.

53. forall Supporters of 2014 prizes. Theranostics. The use of contrast agents in clinical and preclinical PET-MR imaging. PET Clin. 2016; 11: 119-128.

54. Lee CM, Jeong HJ, Kim EM, Kim DW, Lim ST, Kim HT, et al. Superparamagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocellular carcinoma. Magn Reson Med. 2009; 62: 1440-6.

55. Tu C, Ng TS, Jacobs RE, Louie AY. Multimodality PET/MRI agents targeted to activated macrophages. J Biol Inorg Chem. 2014; 19: 247-58.

56. Jarrett BR, Correa C, Ma KL, Louie AY. In vivo mapping of vascular inflammation using multimodal imaging. PLoS One. 2010; 5: e12354.

57. de Rosales RTM. The use of contrast agents in clinical and preclinical PET-MR imaging. PET Clin. 2016; 11: 119-128.

58. Moon SH, Yang BY, Kim YJ, Hong MK, Lee YS, Lee DS, et al. Development of a complementary PET/MR dual-modal imaging probe for targeting prostate-specific membrane antigen (PSMA). Nanomedicine. 2016; 12: 871-9.

59. Shanehsazadeh S, Gruettnner C, Lahooti A, Mahmoudi M, Allen BJ, Ghavami M, et al. Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo. Contrast Media Mol Imaging. 2015; 10: 225-36.

60. Sharma R, Xu Y, Kim SW, Schueller MJ, Alexoff D, Smith SD, et al. Carbon-11 radiolabeling of iron-oxide nanoparticles for dual-modality PET/MR imaging. Nano Lett. 2013; 13: 7092-5.

61. Zhu J, Zhang B, Tian J, Wang J, Chong Y, Wang X, et al. Synthesis of heterodimer radionuclide nanoparticles for magnetic resonance and single-photon emission computed tomography dual-modality imaging. Nanoscale. 2013; 5: 2092-5.

62. Thorek DL, Ulmert D, Diop NFM, Lupu ME, Doran MG, Huang RM, et al. Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. Nat Commun. 2014; 5: 3097.

63. Heuveling DA, Visser GW, Backman M, Roos WH, Wu J, Hoekstra OS, et al. 89Zr-nanocollodial albumin-based PET/CT lymphoscintigraphy for sentinel node detection in head and neck cancer: Preclinical results. J Nucl Med. 2011; 52: 1580-8.

64. Heuveling DA, van Schie A, Vugs DJ, Hendriks NH, Yaqub M, Hoekstra OS, et al. Pilot study on the feasibility of PET/CT lymphoscintigraphy with 89Zr-nanocollodial albumin for sentinel node identification in oral cancer patients. J Nucl Med. 2013; 54: 585-9.

65. Wong RM, Gilbert DA, Lu K, Louie AY. Rapid size-controlled synthesis of dextran-coated, Cu-core iron oxide nanoparticles. ACS Nano. 2012; 6: 3461-7.

66. Boros E, Bowen AM, Josephson L, Vassnev N, Holland JP. Chelate-free metal ion binding and heat-induced radiolabeling of iron oxide nanoparticles. Chem Sci. 2015; 6: 225-36.

67. Yuan H, Wilks MQ, Normandin MD, El Fakhri G, Kaittanis C, Josephson L. Heat-induced radiolabeling and fluorescence labeling of Feraheme nanoparticles for PET/MR imaging and multimodality imaging. ACS Nano. 2013; 7: 47222.

68. Normandin MD, Yuan H, Wilks MQ, Chen HH, Kinsella JM, Cho H, et al. Heat-induced radiolabeling of iron-oxide nanoparticles for dual-modality PET/MR imaging. ACS Nano. 2011; 5: 12299-303.

69. Thorek DL, Thorek MR, Rames N, Pinkweh MW, Wolterbeek HT, Carlin SD, et al. 89Zr-labeled paramagnetic octreotide-liposomes for PET/MRI imaging of cancer. Pharm Res. 2013; 30: 878-88.

70. Sirol M, Foster V, Badimon JJ, Fallon JT, Moreno PR, Troussat JF, et al. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation. 2005; 112: 1594-600.

71. Uppal R, Cesniels K, Chendle DB, Loving GS, Caravan P. Discrete bimodal nanoparticles for multimodal probes for medical applications. Angew Chem Int Ed. 2011; 50: 12299-303.

72. Liew M, Maitani Y, Oestreicher R. Atherosclerosis. Circulation. 2008; 117: 379-87.

73. Wang JTW, Fabbro C, Venturelli E, Menard-Moyon C, Chaloin O, Da Ros T, et al. The relationship between the diameter of chemically-functionalized multi-walled carbon nanotubes and their organ biodistribution, profiles in murine models, and the potential for multimodal imaging. Biomaterials. 2014; 35: 720-6.

74. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol. 2007; 2: 47-52.

75. de Rosales RTM. The use of contrast agents in clinical and preclinical PET-MR imaging. PET Clin. 2016; 11: 119-128.

76. Tran LA, Hernandez-Rivera M, Berlin AN, Zheng Y, Sampaio L, Bovee C, et al. The use of gadolinium-carbon nanomaterials to magnetically enhance stem cell retention for cardiovascular cardiomyopathy. Biomaterials. 2014; 35: 720-6.

77. Wang JTW, Fabbro C, Venturelli E, Menard-Moyon C, Chaloin O, Da Ros T, et al. The relationship between the diameter of chemically-functionalized multi-walled carbon nanotubes and their organ biodistribution, profiles in murine models, and the potential for multimodal imaging. Biomaterials. 2014; 35: 720-6.

78. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol. 2007; 2: 47-52.

79. de Rosales RTM. The use of contrast agents in clinical and preclinical PET-MR imaging. PET Clin. 2016; 11: 119-128.

80. de Rosales RTM. The use of contrast agents in clinical and preclinical PET-MR imaging. PET Clin. 2016; 11: 119-128.
112. Hwang DW, Ko HY, Lee JH, Kang H, Ryu SH, Song IC, et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer. Theranostics. 2018; 8: 2683-91.

113. Madrur R, Tran TA, Axelsson J, Ingvar C, Bibic A, Stählenberg F, et al. Ga-laurelabeled superparamagnetic iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes. Am J Nucl Med Mol Imaging. 2014; 6: 343-51.

114. Kim JS, Kim Y-H, Kim JH, Kang KW, Tae EL, Youn H, et al. Development and in vivo imaging of a PET/MR nanoprobe with enhanced NIR fluorescence by eye-encasing formulation. Nanomedicine (Lond). 2012; 7: 219-29.

115. Kobayashi H, Kawamoto S, Bernardo M, Brechbiel MW, Knopp MV, Choyke PL. Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging. J Control Release. 2006; 111: 343-51.

116. Nakajima M, Takeda M, Kobayashi M, Suzuki S, Ohuchi N. Nano-sized fluorescent nanoparticles as new tracers for sentinel node detection: experimental model for decision of appropriate size and wavelength. Cancer Sci. 2005; 96: 352-6.

117. Hwang DW, Ko HY, Lee JH, Kang H, Ryu SH, Song IC, et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med. 2010; 51: 98-105.

118. Wang C, Xu C, Zeng H, Sun S. Recent progress in syntheses and applications of dumbbell-like nanoparticles. Adv Mater. 2009; 21: 3045-52.

119. Xu C, Xie J, Ho D, Wang C, Kohler N, Walsh EG, et al. Au-Fe3O4 dumbbell nanoparticles as dual-functional probes. Angew Chem Int Ed. 2008; 47: 173-6.

120. Yu H, Chen H, Rice PM, Wang SX, White RL, Sun S. Dumbbell-like bifunctional Au-Fe3O4 nanoparticles. Nano Lett. 2005; 5: 379-82.

121. Yang M, Cheng K, Qi S, Liu H, Jiang Y, Jiang H, et al. Affibody modified and radiolabeled gold–iron oxide hetero-nanostructures for tumor optical, PET and MR imaging. Biomaterials. 2013; 34: 2796-806.

122. Jin Q, Zhu W, Jiang D, Zhang R, Kutyreff CJ, Engle JW, et al. Ultra-small iron-gallium acid coordination polymer nanoparticles for chelator-free labeling of 64Cu and multimodal imaging-guided photothermal therapy. Nanoscale. 2017; 9: 12609-17.

123. Kumar R, Nyk M, Ohukansky TK, Flask CA, Prasad PN. Combined optical and MR bioimaging using rare earth ion doped Na2YF6:Yb3+ nanocrystals. Adv Funct Mater. 2009; 19: 853-9.

124. Park YI, Kim JH, Lee KT, Jeon KS, Bin Na H, Yu JH, et al. Nonblinking and nonbleaching upconverting nanoparticles as an optical imaging nanoprobe and TI magnetic resonance imaging contrast agent. Adv Mater. 2009; 21: 4467-71.

125. Zhou J, Sun Y, Du X, Xiong L, Hu H, Li F. Dual-modality in vivo imaging using rare-earth nanocrystals with near-infrared to near-infrared (NIR-to-NIR) upconversion luminescence and magnetic resonance properties. Biomaterials. 2010; 31: 3287-95.

126. Hu H, Li D, Liu S, Wang M, Moats R, Conti PS, et al. Integrin αvβ3-targeted Gd(III)@NaYF4:Er@Eu(III) ultrathin nanoshell for multimodal PET/MR imaging. Biomaterials. 2014; 35: 8649-58.

127. Huang X, Zhang F, Lee S, Swierczewska M, Kiesewetter DO, Lang L, et al. Long-term multimodal imaging of tumor draining sentinel lymph nodes using mesoporous silica-based nanoprobes. Biomaterials. 2012; 33: 4570-8.

128. Zhou J, Yu M, Sun Y, Zhang X, Zhu X, Wu Z, et al. Fluorine-18-labeled Gd(III)/Yb(III)/Eu(III) co-doped Na2YF6:Yb3+ nanophosphors for multimodality PET/MR/UCI imaging. Biomaterials. 2011; 32: 1148-56.

129. Lee J, Lee TS, Ryu J, Hong S, Kang M, Im K, et al. RGD peptide-conjugated multimodal NaGdF4@Yb/Er3+ nanophosphors for upconversion luminescence, MR, and PET imaging of tumor angiogenesis. J Nucl Med. 2013; 54: 96-103.

130. Zhong C, Yang P, Li X, Li C, Wang D, Gai S, et al. Monodisperse bifunctional Fe3O4@NaGdF4:Yb/Er@NaGdF4:Yb/Er core-shell nanocrystals. RSC Advances. 2012; 2: 3194-7.

131. Xia A, Gao Y, Zhou J, Li C, Yang T, Wu D, et al. Core-shell NaYF4:Yb3+ upconversion luminescence imaging probes for targeting T2-enhanced magnetic resonance and NIR-to-NIR upconversion luminescent imaging of small-animal lymphatic nodes. Biomaterials. 2011; 32: 7280-8.

132. He H, Xie MY, Ding Y, Xu YF. Synthesis of Fe3O4@LaF3:Ce3+ Tb nanocomposites with bright fluorescence and strong magnetism. Appl Surf Sci. 2009; 255: 4623-6.

133. Cui X, Matte D, Kovacs NM, Horvath I, Jaruwegi-Itosoro M, de Rosales RMT, et al. Synthesis, characterization, and application of core-shell nanoparticles of Fe3O4@NaYF4(Yb, Er) and Fe3O4@NaYF4(Yb,Tm) nanoparticle as Trimodal (MRI, PET/SPECT, and optical) imaging agents. Biocconjugate Chem. 2016; 27: 319-28.